Clozapine‐induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness

Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment‐resistant schizophrenia, even in 22qDS.

Detalles Bibliográficos
Autores principales: Accinni, Tommaso, Frascarelli, Marianna, Ghezzi, Francesco, Panzera, Alessia, Buzzanca, Antonino, Fanella, Martina, Di Bonaventura, Carlo, Carlone, Luca, Girardi, Nicoletta, Pasquini, Massimo, Di Fabio, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142464/
https://www.ncbi.nlm.nih.gov/pubmed/34084508
http://dx.doi.org/10.1002/ccr3.4134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142464/
https://www.ncbi.nlm.nih.gov/pubmed/34084508
http://dx.doi.org/10.1002/ccr3.4134

Ejemplares similares